These data are consistent with the mechanism of action of this class of therapeutic agents and show that blocking PD1/PD-L1 interaction with avelumab, durvalumab and atezolizumab restored the cytotoxic activity of CTLs and promotes anti-tumor activity by inducing apoptosis in both A498 and 786-O ccRCC cells. Here, CD274 is linked to nonpapillary renal cell carcinoma.